Biovolutions launched several Nanobiotechnology formulation development contracts
June, 2009
BioVolutions launched several Nanobiotechnology formulation development contracts with local and international clients.
BioVolutions signs LOI with Apredica Inc.
October 1st, 2008
BioVolutions signs LOI with Apredica Inc. to complement its formulation
expertise with Apredica's ADME and Toxicology know-how
BioVolutions signs contract with NuCryst Pharmaceuticals
November 2006 - BioVolutions signs contract with NuCryst Pharmaceuticals
for the development of topical formulations including nanocrystalline
silver, a proprietary nanoparticulate API of NuCryst Pharmaceuticals. "We
are delighted to have BioVolutions' highly dedicated team help
us formulate such a complex system", says President and
CEO Scott Gillis.
|
